Navigation Links
Studies Show Effect of BYDUREON™ on A1C and Weight for Up to Three Years
Date:6/24/2011

ve severe kidney problems and should be used with caution in people who have had a kidney transplant. Patients should talk with their healthcare provider if they have severe problems with their stomach, such as delayed emptying of the stomach (gastroparesis) or problems with digesting food. Antibodies may develop with use of BYETTA. Patients who develop high titers to exenatide could have worsening or failure to achieve adequate glycemic control. Consider alternative therapy if this occurs. Severe allergic reactions can happen with BYETTA. There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with BYETTA or any other antidiabetic drug.

The most common side effects with BYETTA include nausea, vomiting, diarrhea, dizziness, headache, feeling jittery, and acid stomach. Nausea most commonly happens when first starting BYETTA, but may become less over time.

These are not all the side effects from use of BYETTA. A healthcare provider should be consulted about any side effect that is bothersome or does not go away.

For additional important safety information about BYETTA, please see the full Prescribing Information (www.byetta.com/pi) and Medication Guide (www.byetta.com/mg).

About Amylin, Lilly and Alkermes

Amylin and Lilly partnered to develop and market BYDUREON, which is based on proprietary technology for long-acting medications developed by Alkermes, Inc. BYDUREON is approved in the EU and is under regulatory review in the U.S.

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to tr
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Alkermes, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pearl Therapeutics Advances Its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
2. Best of ASCO Features Two Studies Led by US Oncology Research Affiliated Physicians
3. Data from Clinical Studies of bioTheranostics CancerTYPE ID® and Breast Cancer Index(SM) Molecular Diagnostic Tests Presented at ASCO 2011 Annual Meeting
4. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
5. Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
6. Additional Data From Multiple Phase 1 and 2 Studies of S*BIOs Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
7. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
8. Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
9. Lilly Oncology to Unveil Data From More Than 30 Studies at ASCO
10. New Studies Support CardioFocus HeartLight™ Endoscopic Ablation Systems Notable Treatment Results for Paroxysmal Atrial Fibrillation
11. Esperion Announces Results From Phase 1 Study and Four Preclinical Studies for ETC-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014  Air Products (NYSE: ... of medical oxygen is vital to any healthcare facility. ... that not only improve the efficiency of its oxygen ... will highlight these systems—including systems for emergency oxygen ... loss—from August 4-5 at the 51 st ...
(Date:7/28/2014)... 28, 2014 Research and Markets  has announced ... 2014-2018" report to their offering. ... that leads to inflammation and pain in the human body,s ... addition, it causes inflammation of the tissues that surround the ... symptoms of RA begin slowly, usually just mild pain around ...
(Date:7/28/2014)... , July 28, 2014  TNI BioTech, Inc. ... company focused on the development, marketing and distribution ... filed definitive proxy materials with the Securities and ... Meeting of Shareholders to be held on Thursday, ... Time. The record date for determining those shareholders ...
Breaking Medicine Technology:Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 2Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 3Global Rheumatoid Arthritis Drugs Market 2014-2018 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3
... The U.S. Food and Drug Administration today announced that monthly ... Letairis tablets (ambrisentan), used to treat high blood pressure in ... hypertension, or PAH). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... the FDA said that the drug poses only a low ...
... 4, 2011 Sigma-Aldrich Corporation (Nasdaq: SIAL ) ... 31st Annual Cowen and Company Healthcare Conference ... Place, Boston, MA, presenting at 10:15 AM (EST). Barclays ... the Loews Miami Hotel, Miami, FL, presenting at 10:15 AM ...
Cached Medicine Technology:FDA Modifies Boxed Warning For Pulmonary Arterial Hypertension Drug Letairis 2FDA Modifies Boxed Warning For Pulmonary Arterial Hypertension Drug Letairis 3
(Date:7/28/2014)... 29, 2014 The “Tissue ... Hybridization, Digital pathology & Workflow, Special Staining), ... Cancer, Non Small Cell Lung Cancer and ... Pharmaceutical companies, Research Laboratories, Contract Research Organizations ... Europe, BRIC, Japan & RoW) - Trends ...
(Date:7/28/2014)... Ariz (PRWEB) July 28, 2014 ... on a new camp property in Cornville, AZ. ... seriously ill children with the opportunity to attend ... campers and families. The organization offers a variety ... 6-15 with chronic and life threatening illnesses including: ...
(Date:7/28/2014)... 28, 2014 An estimated 68,000 women ... metastatic breast and prostate cancers – an aggressive form ... spread to other parts of the body, such as ... Drexel University College of Medicine have developed ... inhibits metastatic progression by blocking tumor cells from “re-seeding.” ...
(Date:7/28/2014)... a surgical procedure to treat severe chronic migraine headaches ... of the time in patients treated at Massachusetts General ... Plastic and Reconstructive Surgery report that more than half ... all of whom had headaches associated with compression of ... later. The team,s paper has received advance online ...
(Date:7/28/2014)... Glutamine is the most abundant single amino ... conditionally essential during times when the body undergoes large ... Immune System Support. , Having a heavy work out ... with additional glutamine may be advantageous. Glutamine supplementation may ... digestion and immune system function. Stress on the body ...
Breaking Medicine News(10 mins):Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 3Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 4Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 5Health News:Camp Soaring Eagle Announces New Camp Site 2Health News:Camp Soaring Eagle Announces New Camp Site 3Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 2Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 3Health News:Non-endoscopic migraine surgery provides significant symptom relief 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3
... the blood is not associated with a reduced risk ... online May 27 in the Journal of the ... high doses of vitamin D may reduce the risk ... the relationship have reported inconsistent results. , In a ...
... finds evidence of slight link between higher concentrations, aggressive ... Men with a high blood concentration of vitamin D ... Cancer Institute researchers report. , Previous laboratory studies had ... prostate cancer risk, but epidemiological studies of that association ...
... Researchers have uncovered a completely unexpected way that the brain ... protective protein to nearby neurons. , Astrocytes are a type ... one of their roles is to chew up damaged nerves ... damaged area. , Roger Chung and colleagues have now ...
... higher in low-expenditure areas than in high-expenditure ones, study ... levels of spending on medical care don,t improve patients, ... who conducted a survey of Medicare beneficiaries. , Per ... United States and differences in health don,t account for ...
... review suggests they may help cancer cells resist chemo, ... new review of existing research suggests that cancer patients ... of antioxidants. , Although multivitamins may be all right ... or E supplements can spell trouble, said review author ...
... Environmentally friendly is not a phrase normally used to ... discovery at Tel Aviv University, the chemical industry is ... Arkadi Vigalok from the School of Chemistry at Tel ... to make certain steps of a complicated chain of ...
Cached Medicine News:Health News:No association found between vitamin D concentration in blood and risk of prostate cancer 2Health News:Vitamin D Status Not Associated With Lower Prostate Risk 2Health News:Spending Doesn't Improve Patients' Perception of Care 2Health News:Cancer Patients Should Steer Clear of Antioxidants 2Health News:Cancer Patients Should Steer Clear of Antioxidants 3Health News:1 small step for a lab science, 1 green leap for mankind 2
... to use: when presented in convenient, ... easy to pick up directly from ... the 96 tips are loaded without ... with a security sticker. Fully autoclavable, ...
This pipette tip facilitates the loading of samples onto polyacrylamide gels for DNA sequencing. The Geloader Tip has a 15 mm capillary with a defined diameter of less than 0.3 mm. The flexibility of...
1200 L, Racked, 96 tips/rack, 10 racks/box Recommended for 1200 L SofTouch electronic pipettes....
Designed to fit the Brinkmann Tranferpette and Treff Multi-Channel 300 L Pipettors, this tip provides extra space for repeat pipetting....
Medicine Products: